The AGO-OV-229 trial confirmed that adding the PD-L1 inhibitor Atezolizumab to bevacizumab and chemotherapy did not improve overall or progression-free survival, reinforcing the challenge of applying immunotherapy in this setting.
Despite stratifying patients by PD-L1 status, the AGO-OV-229 trial found it was not a predictive marker. Hazard ratios for survival were similar for both PD-L1 positive and negative tumors, challenging its utility for patient selection.
Although the overall trial was negative, exploratory analysis of the AGO-OV-229 study suggested patients previously treated with Bevacizumab derived more benefit from Atezolizumab, hinting at a potential synergy worth further investigation.